---
title: "Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293663023.md"
description: "Dyne Therapeutics closed an upsized public offering of 21,045,000 common shares at $20.50 per share on July 23, 2026, raising approximately $431.4 million in gross proceeds. This amount includes the full exercise of the underwriters' option to purchase additional shares. The capital will support the clinical-stage company's mission to treat genetically driven neuromuscular diseases."
datetime: "2026-07-23T20:08:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293663023.md)
  - [en](https://longbridge.com/en/news/293663023.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293663023.md)
---

# Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

On July 23, 2026, Dyne Therapeutics, Inc. completed an upsized underwritten public offering of 21,045,000 shares of its common stock on the Nasdaq under the symbol DYN. Each share was priced at $20.50, resulting in gross proceeds of about $431.4 million for Dyne. This figure includes 2,745,000 shares from the underwriters exercising their full option to purchase additional shares. The offering, in which all shares were sold by Dyne, aimed to support the clinical-stage company's mission of providing functional improvement for individuals with genetically driven neuromuscular diseases.

### Related Stocks

- [DYN.US](https://longbridge.com/en/quote/DYN.US.md)

## Related News & Research

- [Dyne Therapeutics (DYN) Could Be 38% Undervalued As FDA Milestones Lift Pipeline Hopes](https://longbridge.com/en/news/294589043.md)
- [Dyne Therapeutics director Dirk Kersten disposes of 261,460 common shares worth $6.67 million](https://longbridge.com/en/news/294254633.md)
- [Cleerly partners with Allelica to launch polygenic risk score test for coronary artery disease](https://longbridge.com/en/news/294421513.md)
- [Dyne Therapeutics Upsized Equity Offering Strengthens Cash Runway](https://longbridge.com/en/news/293529976.md)
- [Kazia Therapeutics Files Provisional Patent Backing New Paxalisib Strategy in High-Risk Early TNBC](https://longbridge.com/en/news/294061781.md)